Showing results (391-400 of 470) with videos related to
Sort By:
Pageof 47
Clinical Pharmacology and Therapeutics|January 17, 2019
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2Tanda M Dudenkov, Duan Liu, Junmei Cairns, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2024
Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective TrialTufia C Haddad, Vera J Suman, Karthik V Giridhar, et al.Breast Cancer Research and Treatment|January 3, 2021
A clinical calculator to predict disease outcomes in women with triple-negative breast cancerMei-Yin C Polley, Roberto A Leon-Ferre, Samuel Leung, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system databaseQian Shi, Aimery de Gramont, Axel Grothey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2017
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive DatabaseLindsay A Renfro, Richard M Goldberg, Axel Grothey, et al.NAR Cancer|June 23, 2022
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy responseKevin J Thompson, Roberto A Leon-Ferre, Jason P Sinnwell, et al.The Journal of Clinical Investigation|May 1, 2018
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabineJia Yu, Bo Qin, Ann M Moyer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORxLynne I Wagner, Robert J Gray, Joseph A Sparano, et al.The Lancet. Oncology|December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialStephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast CancerMariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, et al.Pageof 47